Therapy Areas: Diabetes
ANI Pharmaceuticals secures FDA approval for ILUVIEN label expansion
14 March 2025 - Biopharmaceutical company ANI Pharmaceuticals Inc (Nasdaq:ANIP) announced on Friday that the US Food and Drug Administration has approved an expanded label for ILUVIEN, adding an indic...
Kodiak Sciences completes enrolment in GLOW2 Phase 3 trial of tarcocimab tedromer in diabetic retinopathy
11 March 2025 - US biopharmaceutical company Kodiak Sciences Inc (Nasdaq:KOD) announced on Monday that it has completed enrolment in its GLOW2 Phase 3 clinical trial of tarcocimab tedromer in patients...
Sterotherapeutics launches Phase 2 clinical trial of ST-002 for Cushing's Syndrome
25 February 2025 - US biopharmaceutical company Sterotherapeutics announced on Monday that it has launched a Phase 2 clinical trial of ST-002, a novel drug candidate for patients with Cushing's S...
FDA accepts Alvotech and Teva's application for Eylea biosimilar
18 February 2025 - Biotech company Alvotech S.A. (NASDAQ:ALVO) and Teva Pharmaceuticals, a US affiliate of Israel-based pharmaceutical company Teva Pharmaceutical Industries Ltd (NYSE:TEVA) (TASE:TEVA...
Owens & Minor launches ByramConnect digital health platform for diabetes management
11 February 2025 - Healthcare solutions company Owens & Minor Inc (NYSE:OMI) on Tuesday introduced ByramConnect, a digital health platform designed to support Byram Healthcare customers managing d...
NLS Pharmaceutics and Kadimastem plan multi-target approach to diabetes
11 February 2025 - Swiss clinical-stage biopharmaceutical company NLS Pharmaceutics Ltd (Nasdaq: NLSP) and Kadimastem Ltd (TASE: KDST), an Israeli clinical-stage cell therapy company, said on Monday t...